Sundry Photography / Shutterstock.com
Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Roche, Area Pharmaceuticals, COVID-19, antiviral, AT-527, biotechnology, pandemic, RNA